iBio, Inc. (IBIO) financial statements (2021 and earlier)

Company profile

Business Address 600 MADISON AVENUE, SUITE 1601
NEW YORK, NY 10022-1737
State of Incorp. DE
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
6/30/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments441682394
Cash and cash equivalents441682394
Receivables0000100
Prepaid expense     00
Other current assets     00
Other undisclosed current assets00000  
Total current assets:4516924104
Noncurrent Assets
Finance lease, right-of-use asset28
Property, plant and equipment32425262600
Intangible assets, net (including goodwill)1122223
Intangible assets, net (excluding goodwill)1122223
Other undisclosed noncurrent assets00000  
Total noncurrent assets:322627272823
TOTAL ASSETS:3631433652126
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1222210
Accounts payable0111110
Accrued liabilities1111100
Deferred revenue3
Debt00000  
Due to related parties     00
Contract with customer, liability1
Other undisclosed current liabilities   00 (0)
Total current liabilities:5322210
Noncurrent Liabilities
Long-term debt and lease obligation3225252525  
Finance lease, liability32
Capital lease obligations25252525  
Total noncurrent liabilities:3225252525  
Other undisclosed liabilities     (0) 
Total liabilities:372827272810
Stockholders' equity
Stockholders' equity attributable to parent(1)216910116
Common stock0000000
Additional paid in capital13510810481675947
Accumulated other comprehensive loss(0)(0)(0)(0)(0)(0) 
Accumulated deficit(136)(106)(88)(72)(58)(48)(41)
Stockholders' equity attributable to noncontrolling interest(0)(0)(0)014  
Total stockholders' equity:(1)216924116
TOTAL LIABILITIES AND EQUITY:3631433652126

Income statement (P&L) ($ in millions)

12/31/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
6/30/2014
Revenue, net 0120
Gross profit:2200120
Operating expenses(17)(18)(15)(15)(11)(9)(4)
Operating loss:(15)(16)(14)(14)(10)(7)(4)
Nonoperating income (expense)(2)(2)(2)(2)(1)00
Investment income, nonoperating0000000
Interest and debt expense(2)(2)(2)(2)(1)  
Loss from continuing operations before income taxes:(19)(19)(18)(18)(11)(7)(4)
Income tax benefit     31
Loss before gain (loss) on sale of properties:(19)(19)(18)(18)(11)(4)(2)
Other undisclosed net income22221  
Net loss:(17)(18)(16)(16)(11)(4)(2)
Net income attributable to noncontrolling interest00021  
Other undisclosed net loss attributable to parent     (3)(1)
Net loss attributable to parent:(17)(18)(16)(15)(10)(7)(4)
Other undisclosed net loss available to common stockholders, basic(22)(0)(0)(0)   
Net loss available to common stockholders, diluted:(39)(18)(16)(15)(10)(7)(4)

Comprehensive Income ($ in millions)

12/31/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
6/30/2014
Net loss:(17)(18)(16)(16)(11)(4)(2)
Other undisclosed comprehensive loss(0)(0)(0) (0)(3) 
Comprehensive loss:(17)(18)(16)(16)(11)(7)(2)
Comprehensive income, net of tax, attributable to noncontrolling interest00021  
Comprehensive loss, net of tax, attributable to parent:(17)(18)(16)(15)(10)(7)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: